在由斯科波胺诱导的老鼠中,TeMacTM改善了记忆障碍和胆功能障碍
Bruno Dupon Akamba Ambamba1,2, Fils Armand Ella1,2, Dany Joël Ngassa Ngoumen1,2
1Department of Biochemistry, Faculty of Science, University of Yaoundé 1, P.O. Box 812, Yaounde, Cameroon.
Metabolic brain disease
|January 14, 2025
概括
在阿尔茨海默病的老鼠模型中,TeMacTM通过降低胆酶活性来预防记忆缺陷. 这种天然化合物在治疗与阿尔茨海默病相关的认知障碍方面表现有前途.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学 是一个学科.
- 生物化学 生物化学
背景情况:
- 阿尔茨海默病 (AD) 的特点是与胆固醇功能障碍相关的认知障碍.
- 在老鼠中,scopolamine诱导的认知缺陷可以作为研究AD相关记忆丧失的模型.
研究的目的:
- 评估TeMacTM在预防AD的斯科波拉胺诱导老鼠模型中的记忆障碍的有效性.
- 通过in silico方法识别TeMacTM的活性化合物及其抑制乙胆酶的潜力.
主要方法:
- 用莫里斯水迷宫和新型物体识别测试来评估认知功能.
- 分析了胆酶活性,组织病理学和TeMacTM成分.
- 在的分子对接被用来预测血脑屏障的透和乙胆酶抑制.
主要成果:
- 在老鼠中,TeMacTM的使用显著预防了记忆力缺陷,并降低了胆酶活性.
- 组织病理学分析显示,TeMacTM能够防止神经元损失和海马体的形态变化.
- 在TeMacTM中发现了七种化合物,其中甲酸B和树脂醇显示出穿越血脑屏障和抑制乙胆酶的潜力.
结论:
- TeMacTM在预防和管理阿尔茨海默病的认知障碍方面表现出潜力.
- 该化合物的机制涉及降低胆酶活性和保护海马神经元.
- 已识别的活性化合物为开发AD的新治疗策略提供了基础.
更多相关视频
05:54Author Spotlight: Exploring Acupuncture in Alzheimer's Research from Thread-Embedding Techniques to Clinical Trials
Published on: May 10, 2024
1.3K
08:28Using Pharmacological Manipulation and High-precision Radio Telemetry to Study the Spatial Cognition in Free-ranging Animals
Published on: November 6, 2016
6.7K
相关概念视频
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
95
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
95
Alzheimer's Disease: Treatment
161
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
161
Parkinson's Disease: Treatment
206
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
206
